AuGC BioFund LP and related filers report beneficial ownership of 5.3% of Palatin Technologies common stock. The filers state they each have beneficial ownership of 94,212 shares of Common Stock of Palatin Technologies Inc.
The ownership percentage is based on 1,772,199 shares outstanding as of February 13, 2026. The statement discloses shared voting and shared dispositive power over 94,212 shares and includes an express disclaimer under Rule 13d-4 regarding beneficial ownership.
Positive
None.
Negative
None.
Insights
Holdings disclosed: 94,212 shares (5.3%) with shared voting/dispositive power.
The filing lists AuGC BioFund LP, AuGC Partners LLC, and Evan Markegard as reporting persons, each associated with the same 94,212-share position. The percentage is anchored to February 13, 2026 outstanding shares.
Disclosure includes a Rule 13d-4 disclaimer; the filers assert adviser/manager roles and shared authority rather than sole beneficial ownership. Subsequent filings may update ownership or voting arrangements.
Key Figures
Reported shares owned:94,212 sharesPercent of class:5.3%Shares outstanding:1,772,199 shares+1 more
4 metrics
Reported shares owned94,212 sharesBeneficial ownership reported by AuGC BioFund LP
Percent of class5.3%Calculated using shares outstanding as of <date>February 13, 2026</date>
Shares outstanding1,772,199 sharesOutstanding common stock as of <date>February 13, 2026</date>
CUSIP696077601Palatin Technologies Common Stock CUSIP
Key Terms
Schedule 13G, beneficial ownership, Rule 13d-4 disclaimer, shared dispositive power
4 terms
Schedule 13Gregulatory
"Item 1. (a) Name of issuer: PALATIN TECHNOLOGIES INC"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Rule 13d-4 disclaimerregulatory
"Pursuant to Rule 13d-4, as amended, AuGC Partners LLC and Mr. Markegard expressly disclaim beneficial ownership"
shared dispositive powerfinancial
"Shared Dispositive Power 94,212.00"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
PALATIN TECHNOLOGIES INC
(Name of Issuer)
Common Stock, par value $0.01 per share
(Title of Class of Securities)
696077601
(CUSIP Number)
04/13/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
696077601
1
Names of Reporting Persons
AuGC BioFund LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
94,212.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
94,212.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
94,212.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
696077601
1
Names of Reporting Persons
AuGC Partners LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
94,212.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
94,212.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
94,212.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
IA, HC, OO
SCHEDULE 13G
CUSIP Number(s):
696077601
1
Names of Reporting Persons
Evan Markegard
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
94,212.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
94,212.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
94,212.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
5.3 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
PALATIN TECHNOLOGIES INC
(b)
Address of issuer's principal executive offices:
4B CEDAR BROOK DRIVE, CRANBURY, NEW JERSEY, 08512.
Item 2.
(a)
Name of person filing:
AuGC BioFund LP
AuGC Partners LLC
Evan Markegard
(b)
Address or principal business office or, if none, residence:
AuGC BioFund LP
c/o AuGC Partners LLC
10875 Kemah Lane
San Diego, CA 92131
AuGC Partners LLC
10875 Kemah Lane
San Diego, CA 92131
Evan Markegard
c/o AuGC Partners LLC
10875 Kemah Lane
San Diego, CA 92131
(c)
Citizenship:
AuGC BioFund LP - Delaware
AuGC Partners LLC - Delaware
Evan Markegard - United States
(d)
Title of class of securities:
Common Stock, par value $0.01 per share
(e)
CUSIP Number(s):
696077601
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
AuGC Partners LLC is an investment adviser that is registered as an Exempt Reporting Adviser with the Securities and Exchange Commission. AuGC Partners LLC, which serves as investment adviser to AuGC BioFund LP (the "Fund"), may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund. Mr. Markegard, as Managing Member of AuGC Partners LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund. Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, AuGC Partners LLC and Mr. Markegard expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that AuGC Partners LLC or Mr. Markegard are the beneficial owner of any of the securities reported herein.
AuGC BioFund LP - 94,212 shares
AuGC Partners LLC - 94,212 shares
Evan Markegard - 94,212 shares
(b)
Percent of class:
Ownership percentage is based on 1,772,199 shares of common stock outstanding, par value $0.01 per share, as of February 13, 2026, as reported by the Issuer on Form 10-Q filed with the Securities and Exchange Commission on February 17, 2026.
AuGC BioFund LP - 5.3%
AuGC Partners LLC - 5.3%
Evan Markegard - 5.3%
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The Fund has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock covered by this Statement.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
See Notes above.
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
AuGC BioFund LP
Signature:
/s/ Evan Markegard
Name/Title:
Managing Member, AuGC Partners LLC, its General Partner
They reported beneficial ownership of 94,212 shares, representing 5.3% of the outstanding common stock. This percentage is calculated using 1,772,199 shares outstanding as of February 13, 2026.
Who filed the Schedule 13G for PTN?
AuGC BioFund LP, AuGC Partners LLC, and Evan Markegard filed the statement. The filing lists the adviser and managing member addresses at an AuGC Partners LLC business address in San Diego, CA.
Do filers claim sole voting or dispositive power over PTN shares?
No. The filing shows 0 shares of sole voting or sole dispositive power and 94,212 shares of shared voting and shared dispositive power for each reporting person.
What disclaimer did the filers include in the PTN filing?
The filers invoke a Rule 13d-4 disclaimer expressly disclaiming beneficial ownership, stating the adviser/manager roles do not constitute an admission of beneficial ownership of the reported securities.
